Ipsen is a global, mid-sized biopharmaceutical company focused on improving patients' lives through research and innovation. With over 5,000 dedicated professionals worldwide, the company operates in 88 countries, bringing transformative medicines to patients across five continents. Ipsen's expertise spans three core therapeutic areas: Oncology, Rare Disease, and Neuroscience, where the team tackles areas of high unmet medical need through cutting-edge research and development.
Founded in 1929 by Dr. Henri Beaufour, Ipsen has built nearly a century of experience in specialty care medicines. The company combines the resources to make real impact with the agility to move fast, aiming to deliver at least one new molecular entity or meaningful indication every year. With global hubs in the U.S., France, and the U.K., Ipsen maintains an entrepreneurial mindset while scaling its operations to serve patients worldwide.